Skip to main content
Journal cover image

CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon

Publication ,  Journal Article
Venook, A; Niedzwiecki, D; Lenz, HJ; Innocenti, F; Mahoney, MR; O'Neil, B; Shaw, J; Polite, B; Hochster, H; Atkins, J; Goldberg, R; Mayer, R ...
Published in: Annals of Oncology
June 1, 2014

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Annals of Oncology

DOI

EISSN

1569-8041

ISSN

0923-7534

Publication Date

June 1, 2014

Volume

25

Start / End Page

ii112

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Venook, A., Niedzwiecki, D., Lenz, H. J., Innocenti, F., Mahoney, M. R., O’Neil, B., … Blanke, C. (2014). CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon. Annals of Oncology, 25, ii112. https://doi.org/10.1093/annonc/mdu193.19
Venook, A., D. Niedzwiecki, H. J. Lenz, F. Innocenti, M. R. Mahoney, B. O’Neil, J. Shaw, et al. “CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon.” Annals of Oncology 25 (June 1, 2014): ii112. https://doi.org/10.1093/annonc/mdu193.19.
Venook A, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O’Neil B, Shaw J, Polite B, Hochster H, Atkins J, Goldberg R, Mayer R, Schilsky R, Bertagnolli M, Blanke C. CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon. Annals of Oncology. 2014 Jun 1;25:ii112.
Journal cover image

Published In

Annals of Oncology

DOI

EISSN

1569-8041

ISSN

0923-7534

Publication Date

June 1, 2014

Volume

25

Start / End Page

ii112

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis